ArticleJournal of neurology2024

COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.

Alvino Bisecco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.